CANCER RELEVANCE: – mCRC – NSCLC – Pancreatic DRUG RELEVANCE: – Anti-EGFR (cetuximab, panitumumab) – EGFR small molecular inhibitors (gefitinib, erlotinib) SENSITIVITY: – <1% mutant allele TURN AROUND TIME: – 4 to 6 days

Close

previous | zoom | next

KRAS mutation status is a widely adopted predictive molecular diagnostic pertaining to patient response to Anti-EGFR colon cancer therapy. MolecularMD offers sensitive and rapid clinical testing to identify the predominant resistant mutant forms of the KRAS oncogene.

Our comprehensive molecular diagnostic CLIA/CAP services support demanding international clinical research programs, as well as, healthcare providers who seek the most dependable KRAS testing available.

Click here to download the PDF test summary or contact MolecularMD directly for more information.